Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 4Withdrawn 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 5Expanded_access 2

Sponsor

Cancer Type

Genitourinary 5Gastrointestinal 2CNS 2

Conditions

Prostatic Neoplasms 4Prostate Cancer Patients 1

Interventions

Docetaxel 390pembrolizumab 326Prednisone 285Gemcitabine 273enzalutamide 256Radiotherapy 251Nivolumab 248Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 198Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 99abiraterone 99cabozantinib 98atezolizumab 97Sorafenib 97Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × carbon-11 acetate × Genitourinary × Clear all
NCT02715583 2022-05-18

C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate Cancer

Abramson Cancer Center at Penn Medicine

Phase EARLY_PHASE1 Completed
6 enrolled
Genitourinary

Prostate Cancer Patients

NCT01304485 2019-03-07

PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma

Phoenix Molecular Imaging

Phase 2 Completed
2,000 enrolled
Genitourinary

Prostatic Neoplasms

NCT01144897 2018-10-02

PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy

University of Iowa

Phase 1 Completed
5 enrolled
Genitourinary

Prostatic Neoplasms

NCT00924313 2017-07-11

Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
40 enrolled 17 charts
Genitourinary

Prostatic Neoplasms

NCT02169063 2016-08-31

Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer

University of Washington

Phase NA Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡